Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Up 2% – Time to Buy?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) shot up 2% on Monday . The stock traded as high as $6.32 and last traded at $6.12. 33,255 shares changed hands during trading, a decline of 34% from the average session volume of 50,205 shares. The stock had previously closed at $6.00.

Analysts Set New Price Targets

Separately, Jones Trading initiated coverage on shares of Armata Pharmaceuticals in a research note on Monday, January 5th. They set a “buy” rating and a $15.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $12.00.

Armata Pharmaceuticals Stock Performance

The company’s 50 day moving average price is $6.35 and its 200 day moving average price is $4.45. The company has a market cap of $222.83 million, a price-to-earnings ratio of -3.78 and a beta of 1.29.

Institutional Trading of Armata Pharmaceuticals

An institutional investor recently raised its position in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC lifted its position in shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) by 17.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,988 shares of the company’s stock after purchasing an additional 6,034 shares during the quarter. SeaCrest Wealth Management LLC owned 0.11% of Armata Pharmaceuticals worth $274,000 at the end of the most recent reporting period. 3.57% of the stock is currently owned by institutional investors and hedge funds.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.